The Company operates in one business segment: pharmaceuticals. The Company's current pharmaceutical franchises are divided between the dermatological and non-dermatological fields. The dermatological field represents products for the treatment of acne and acne-related dermatological conditions and non-acne dermatological conditions. The non-dermatological field represents products for the treatment of urea cycle disorder, contract revenue, and beginning on December 2, 2011 upon the Company's acquisition of the assets of Graceway, products in the respiratory and women's health specialties. The acne and acne-related dermatological product lines include SOLODYN® and ZIANA®. During early 2011, the Company discontinued its TRIAZ® branded products and decided to no longer promote its PLEXION® branded products. The non-acne dermatological product lines include DYSPORT®, LOPROX®, PERLANE®, RESTYLANE®, VANOS® and ZYCLARA®. ZYCLARA® was acquired by the Company as part of the acquisition of the assets of Graceway on December 2, 2011. The non-dermatological product lines include AMMONUL® and BUPHENYL®. The non-dermatological field also includes contract revenues associated with licensing agreements and authorized generic agreements.

The Company's pharmaceutical products, with the exception of AMMONUL® and BUPHENYL®, are promoted to dermatologists and plastic surgeons. Such products are often prescribed by physicians outside these two specialties, including family practitioners, general practitioners, primary-care physicians and OB/GYNs, as well as hospitals, government agencies, and others. Currently, the Company's products are sold primarily to wholesalers and retail chain drug stores. During 2011, 2010 and 2009, three wholesalers accounted for the following portions of the Company's net revenues:

	YEARS ENDED DECEMBER 31,
	2011	2010	2009

McKesson	44.3%	42.6%	40.8%
Cardinal	38.3%	35.4%	37.1%
AmerisourceBergen	*	10.8%	*

* less than 10%

McKesson is the sole distributor for the Company's RESTYLANE® and PERLANE® branded products and DYSPORT® in the U.S.

Net revenues and the percentage of net revenues for each of the product categories are as follows (amounts in thousands):

	YEARS ENDED DECEMBER 31,
	2011		2010		2009

Acne and acne-related dermatological products	$	447,585	$	482,359	$	398,861
Non-acne dermatological products		229,603		174,978		133,595
Non-dermatological products		43,938		38,595		38,191
Total net revenues	$	721,126	$	695,932	$	570,647


		YEARS ENDED DECEMBER 31,
		2011		2010		2009

Acne and acne-related dermatological products		62	%	69	%	70	%
Non-acne dermatological products		32		25		23
Non-dermatological products		6		6		7
Total net revenues		100	%	100	%	100	%

During 2011, 2010 and 2009, the Company's top three products constituted 72.1%, 72.9% and 72.0%, respectively, of its total net revenues. Less than 5% of the Company's net revenues during 2011, 2010 and 2009 were generated outside the U.S.